MedTrace Logo

An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability

NCT04161482 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2020-07-10

No results posted yet for this study

Summary

This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix.

Conditions

  • Healthy

Interventions

DRUG

Furosemide 80 mg (8 mg/mL)

Furoscix will be administered as a subcutaneous infusion.

Sponsors & Collaborators

  • Clinical Trial Data Services, Inc.

    collaborator UNKNOWN

  • CSSi Life Sciences

    collaborator INDUSTRY

  • scPharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Samir Arora, MD · Aventiv Clinical Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2020-06-24
Completion
2020-06-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161482 on ClinicalTrials.gov